WS #16090
France is imposing curfews as nationwide riots escalate, with estimated damages in Milan alone exceeding half a million euros. The civil unrest is weighing on European equities, with the CAC 40 down nearly 1.5% as investors digest the political instability. This development dampens the bullish outlook for European consumer discretionary and luxury sectors, as looting and disruption threaten retail operations and consumer confidence. Disc Medicine shares are trading significantly higher after announcing that its Phase 3 APOLLO trial for bitopertin met all primary and secondary endpoints for treating erythropoietic protoporphyria. The stock surged 55-66% in premarket trading, driven by the strong clinical data showing a 41.4% reduction in PPIX and improved pain-free hours. This is a high-conviction bullish signal for the biotech sector, with an NDA resubmission expected by year-end and an FDA decision anticipated in mid-2027.
European Civil Unrest and Political Instability
France is imposing curfews as nationwide riots escalate, with estimated damages in Milan alone exceeding half a million euros. The civil unrest is weighing on European equities, with the CAC 40 down nearly 1.5% as investors digest the political instability. This development dampens the bullish outlook for European consumer discretionary and luxury sectors, as looting and disruption threaten retail operations and consumer confidence.
Disc Medicine shares are trading significantly higher after announcing that its Phase 3 APOLLO trial for bitopertin met all primary and secondary endpoints for treating erythropoietic protoporphyria. The stock surged 55-66% in premarket trading, driven by the strong clinical data showing a 41.4% reduction in PPIX and improved pain-free hours. This is a high-conviction bullish signal for the biotech sector, with an NDA resubmission expected by year-end and an FDA decision anticipated in mid-2027.